NIM1K

Serine/threonine-protein kinase NIM1 · Q8IY84 · NIM1K on Sugi Atlas →

629 patent compounds predicted against NIM1K, 552 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gsk-461364 (SCHEMBL310080)	1.00	1/20
Gsk-461364 (SCHEMBL4276841)	1.00	1/20
Gsk-461364 (SCHEMBL29360650)	1.00	1/20
Gsk-461364 (SCHEMBL29655945)	1.00	1/20
SCHEMBL19196385	0.91	1/20
SCHEMBL25660820	0.89	1/20
SCHEMBL2973906	0.88	1/20
SCHEMBL2973537	0.86	1/20
SCHEMBL4405982	0.86	1/20
SCHEMBL4562944	0.86	1/20
SCHEMBL13573235	0.86	1/20
Hydrochloric Acid (SCHEMBL3107975)	0.85	1/20
Hydrochloric Acid (SCHEMBL3111856)	0.85	1/20
SCHEMBL14029636	0.85	1/20
SCHEMBL25660819	0.85	1/20
Hydrochloric Acid (SCHEMBL4398123)	0.83	1/20
Hydrochloric Acid (SCHEMBL4541913)	0.83	1/20
SCHEMBL25227565	0.83	1/20
SCHEMBL25227566	0.83	1/20
SCHEMBL11923420	0.82	1/20

Clinical trials — most relevant to NIM1K by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas	PHASE1/PHASE2	COMPLETED
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]	PHASE2	UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Pulsed Electro Magnetic Fields (PEMF) in Depression	nan	COMPLETED
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Microvascular Dysfunction and the Development of Whole-body Insulin Resistance	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NIM1K binder may also engage these)

Protein	Name	Similarity
Q8BHI9	—	1.000	Q8BHI9 →
Q8BRK8	—	0.995	Q8BRK8 →
P07934	—	0.994	P07934 →
Q09137	—	0.993	Q09137 →
Q5RDH5	—	0.993	Q5RDH5 →
Q6PFQ0	—	0.992	Q6PFQ0 →
Q5RD00	—	0.992	Q5RD00 →
PRKAA1	5'-AMP-activated protein kinase catalytic subunit alpha-1	0.992	landscape →
CAMK2D	Calcium/calmodulin-dependent protein kinase type II subunit delta	0.992	landscape →
Q8VDF3	—	0.992	Q8VDF3 →
Q95266	—	0.991	Q95266 →
P54645	—	0.991	P54645 →
Q755C4	—	0.991	Q755C4 →
P11730	—	0.991	P11730 →
Q63531	—	0.991	Q63531 →
O19111	—	0.991	O19111 →
P08413	—	0.990	P08413 →
PRKAA2	5'-AMP-activated protein kinase catalytic subunit alpha-2	0.990	landscape →
P13234	—	0.990	P13234 →
Q852Q2	—	0.990	Q852Q2 →
Q2HJF7	—	0.990	Q2HJF7 →
O08875	—	0.990	O08875 →
Q28948	—	0.989	Q28948 →
PHKG2	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	0.989	landscape →
Q5EG47	—	0.989	Q5EG47 →
Q62074	—	0.989	Q62074 →
P10665	—	0.989	P10665 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.989	landscape →
Q5R4K9	—	0.989	Q5R4K9 →
P00518	—	0.989	P00518 →